Ackrell Capital Cannabis Investment Report (Dec 2017) – No substantive investigative leads
Summary
The document is a commercial investment report on the cannabis industry with generic market analysis and no mention of specific individuals, transactions, or wrongdoing. It lacks actionable details, n Report outlines cannabis market segments, legal landscape, and forecasts. Contains standard disclosures and acknowledgments from Ackrell Capital, a FINRA/SIPC member. No references to government offi
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (2)
Tags
Related Documents (6)
Ackrell Capital Cannabis Investment Report compares market size to alcohol, coffee, tobacco, and pharmaceuticals
The document is a commercial investment analysis with no mention of political figures, government agencies, or alleged misconduct. It offers no actionable leads for investigations and contains only pu Provides estimated penetration rates and consumer spending for cannabis versus other legal substance Claims U.S. legal cannabis market size aligns with other retail markets. Published by Ackrell Capi
Ackrell Capital Cannabis Investment Report – Terpene Benefits Overview (Dec 2017)
The passage is a generic industry report describing terpene profiles and alleged medicinal benefits. It contains no references to high‑profile individuals, government agencies, financial transactions, Describes therapeutic claims for various cannabis terpenes (myrcene, pinene, limonene, camphene). Provides a table of purported medical benefits (antianxiety, anti‑inflammatory, etc.). Published by A
Ackrell Capital Cannabis Investment Report – Terpene Profile (Dec 2017)
The document is a technical cannabis industry report containing terpene percentages and formulation data. It mentions no high‑profile individuals, government agencies, financial transactions, or contr Provides typical terpene composition percentages for cannabis flower. Describes the concept of the “Entourage Effect” and THC:CBD ratio ranges. Published by Ackrell Capital, a FINRA/SIPC‑registered f
Ackrell Capital Cannabis Investment Report – Technical Overview of CBDA and Decarboxylation (Dec 2017)
The passage is a purely scientific/financial overview of cannabinoid chemistry and investment context. It contains no mention of political figures, government agencies, financial flows tied to powerfu Describes CBDA as a non‑psychoactive precursor to CBD with potential medical benefits. Notes recent cultivation of cannabis strains with high CBDA levels comparable to THC. Explains decarboxylation p
Cannabis Investment Report – Technical Overview of Cannabis Species and Compounds
The passage is a generic scientific and market overview of cannabis biology and does not mention any political figures, government agencies, financial transactions, or misconduct. It offers no actiona Describes three primary cannabis species and hybrid varieties. Explains cannabinoids (THC, CBD) and terpenes and their effects. Details plant anatomy, focusing on trichomes where compounds concentrat
Cannabis Investment Report (December 2017) – Limited investigative value
The document is a generic product catalog/marketing sheet for cannabis edibles with no mention of political figures, government agencies, financial transactions, or wrongdoing. It provides no actionab Dated December 2017, produced by Ackrell Capital, LLC (FINRA/SIPC member). Lists various cannabis-infused edible products (chocolate, sparkling water, mints, brownies, gummies Contains branding and d
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.